The 18th annual ‘Improving Outcomes in the Treatment of Opioid Dependence’ (IOTOD) meeting took place as a virtual event on the 24–25 September 2020.
The 2020 IOTOD Scientific Committee headed-up the two-day meeting, with international experts invited to speak on topics such as opioid analgesic dependence (OAD), opioid substitution therapy adherance, long-acting buprenorphine formulations, and HIV and HCV. The webcasts from this year’s conference are available to view below.
Polysubstance use: the consequences for opioid substitution therapy
How can we improve adherence and effectiveness of medications for opioid use disorder?
Professor Sir John Strang
Women use drugs too: overcoming the barriers to treatment and care
Optimising care for PWUDs in the prison setting
Tackling the increasing drug problems in Scotland — what else can be done?
Preventing and identifying OAD in patients with chronic pain
I think my pain patient has OAD: what do I do now?
Duncan Hill, Jeremy Hayllar, Michael Kelleher
An overview of long-acting buprenorphine formulations
The perspectives from PWUDs, HCPs and public health
Duncan Hill, Catriona Matheson and Mat Southwell
Hepatitis B virus among PWIDs: the forgotten virus?
Professor Ashley Brown
Can we do more for HCV care among PWIDs?
Unravelling drug-drug interactions of antivirals and OST
Complex cases: panel discussion
Graham Foster, Stephan Walcher, Jane Quinlan, Duncan Hill
The IOTOD conference offers a range of exciting and interactive sessions, involving thought-provoking talks and expert-led panel discussions.
Date: 18th and 19th May 2020
Location: Steigenberger Airpot Hotel, Amsterdam
We are currently looking for sponsorship for the IOTOD 2020 conference. If you are interested in sponsoring this event then please get in touch by emailing email@example.com
Full agenda and accreditation information coming soon!
WHAT’S IN STORE FOR IOTOD 2020?
- Addressing challenges faced during opioid substitution therapy
- Deconstructing stigma: recognising the needs of drug-using populations
- Shining a light on opioid analgesic dependence
- Long-acting buprenorphine formulations: a panoramic view
- Strategies for improving viral hepatitis care among PWIDs
- Complex cases: panel discussion
The IOTOD experience
Measuring behavioural changes
2011 marked the year measurement of delegate behavioural changes began. These measurements showed the IOTOD conference elicited measurable significant improvements in physician behaviours over the years, which have been published in the European Journal of CME.
IOTOD’s commitment to change
Addictions Clinic Medical Director, Medical University of Vienna
Professor of Hepatology, Queen Mary's University of London & Consultant, Bart's Health NHS Trust
Camurus is a Swedish research-based pharmaceutical company with more than 25 years of innovation and leadership in lipid-based drug delivery technologies. For the development of new product candidates, Camurus utilises its own patented FluidCrystal® drug delivery technologies. New proprietary medicines with improved properties and better treatment outcomes are developed by combining these technologies with established and regulatory approved active ingredients. Camurus’ development pipeline contains product candidates that address conditions with distinct and important medical needs, such as cancer, endocrine disorders, metabolic disorders, opioid dependence and chronic pain.
Gilead Sciences, Inc. is a research-based biopharmaceutical company that discovers, develops and commercializes innovative medicines in areas of unmet medical need. The company strives to transform and simplify care for people with life-threatening illnesses around the world. Gilead has operations in more than 35 countries worldwide, with headquarters in Foster City, California.
AbbVie is a global, research-driven biopharmaceutical company committed to developing innovative advanced therapies for some of the world’s most complex and critical conditions. The company’s mission is to use its expertise, dedicated people and unique approach to innovation to markedly improve treatments across four primary therapeutic areas: immunology, oncology, virology and neuroscience. In more than 75 countries, AbbVie employees are working every day to advance health solutions for people around the world.